Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.32 |
| ▸ | MAP3K5 | Q99683 | 5/20 | 0.32 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.31 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.31 |
| ▸ | EED | O75530 | 2/20 | 0.30 |
| ▸ | SUZ12 | Q15022 | 2/20 | 0.30 |
| ▸ | EZH2 | Q15910 | 2/20 | 0.30 |
| ▸ | MAT2A | P31153 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23601336 | 0.90 | TNF (0.33) | ABCG2MAT2A | |
| SCHEMBL23577377 | 0.88 | FNTA (0.34) | MAP3K5PTGS1PTGS2EEDSUZ12 | |
| SCHEMBL31229439 | 0.88 | FNTA (0.34) | MAP3K5PTGS1PTGS2EEDSUZ12 | |
| SCHEMBL23576626 | 0.87 | MAP4K4 (0.36) | ABCG2 | |
| SCHEMBL29909818 | 0.87 | MAP4K4 (0.36) | ABCG2 | |
| SCHEMBL23577460 | 0.85 | NT5E (0.34) | ABCG2PTGS1PTGS2 | |
| SCHEMBL23578530 | 0.85 | ABCG2 (0.33) | ABCG2MAP3K5 | |
| SCHEMBL23577201 | 0.85 | ABCG2 (0.35) | ABCG2 | |
| SCHEMBL29909700 | 0.85 | ABCG2 (0.35) | ABCG2 | |
| SCHEMBL23601243 | 0.85 | ABCG2 (0.32) | ABCG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220324866-A1 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | GILEAD SCIENCES, INC. | 2022-10-13 | — | — | US | disclosed |
| WO-2021130638-A1 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | CARNA BIOSCIENCES, INC. (JP) | 2021-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220324866-A1 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | DGKG, DGKB, DGKK | ABCG2 4216/4885MAP3K5 136/4885PTGS1 1792/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.